Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high‐grade malignancy?

Abstract

Papillary thyroid carcinoma (PTC) is usually indolent; however, some rare subtypes of PTCs, such as columnar cell and hobnail subtypes, carry poor prognosis as an intermediate malignancy between differentiated carcinoma and anaplastic carcinoma. We present the case of a 56‐year‐old Japanese woman having PTC with aggressive behavior showing characteristic histological features of a predominantly fused follicular and focally solid (FFS) pattern. The fused follicular pattern is cribriform‐like without intermingled vessels. This PTC with FFS pattern included frequent mitotic figures, necrosis, lymphovascular invasion, and metastases with high clinical stage. The tumor cells were broadly positive for antibodies to TTF‐1, PAX8, and bcl‐2, and negative for cyclin D1. Ki‐67 labeling index was approximately 10%, and there was occasional positivity of p53. Targeted next generation sequencing analysis only detected a NRAS mutation (Q61K); there was no mutation and no translocation of other genes including BRAF and RET/PTC. To our knowledge, this is first report that PTC shows aggressive FFS growth pattern. The tumor is possibly included in the new category of differentiated high‐grade thyroid carcinoma in the World Health Organization 2022 classification, or in a novel subtype of PTC owing to its characteristic histological feature and intermediate malignancy between differentiated carcinoma and anaplastic carcinoma.

Clinical and Paraclinical Considerations Regarding ki67’s Role in the Management of Differentiated Thyroid Carcinoma—A Literature Review

“…Another study from Thompson et al reported ki67 proliferation index values calculated for DHGTC ranging from 2.3 to 19.6%, with a median of 8.3% and an average of 9.4% in their study performed on 41 subjects [26]. In their case study of DHGTC, Murata et al reported a ki67 proliferation index value of 10%, higher than the aforementioned value [27].…”